logo-loader
viewStarton Therapeutics

Starton Therapeutics moves closer to treating CLL by selecting lead formulation candidate

Starton Therapeutics Inc CEO Pedro Lichtinger tells Proactive the privately-held, Paramus, New Jersey-based group has selected a subcutaneous (under the skin) lenalidomide formulation as the lead formulation candidate for its continuous subcutaneous delivery system (STAR-LLD SC) for chronic lymphocytic leukemia, which is a type of cancer of the blood and bone marrow, and other hematological malignancies.

Lichtinger says STAR-LLD SC clinical trial materials are expected to be shipped in the second quarter of 2021 for initiation of Phase 1/2 clinical studies for CLL in the second half of 2021. This moves the group closer to producing a product to benefit patients.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Starton Therapeutics named herein, including the promotion by the Company of Starton Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ChemioCare advancing 'potentially revolutionary' chemo-induced nausea treatment

ChemioCare CEO Pedro Lichtinger caught up with Proactive's Andrew Scott while in London. Lichtinger outlines the company's vision which is to transform the current treatment of chemotherapy-induced nausea and vomiting through patch technology. He says the first patch in their pipeline...

on 17/7/18

2 min read